Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-1780 tablets, which are intended for treating heart failure in adults with left ventricular ejection fraction ≥ 40% [1] Group 1: Company Developments - The subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. will soon initiate clinical trials for HRS-1780 tablets [1] - The total research and development investment for the HRS-1780 project has reached approximately 67.8 million yuan [1] Group 2: Industry Context - HRS-1780 tablets are classified as mineralocorticoid receptor antagonists and are part of a broader category of treatments for heart failure [1] - Current primary medications for heart failure include angiotensin receptor/neprilysin inhibitors and sodium-glucose cotransporter 2 inhibitors [1]